TY - JOUR T1 - Confirmed central olfactory system lesions on brain MRI in COVID-19 patients with anosmia: a case-series JF - medRxiv DO - 10.1101/2020.07.08.20148692 SP - 2020.07.08.20148692 AU - Yannick Girardeau AU - Yoan Gallois AU - Guillaume De Bonnecaze AU - Bernard Escudé AU - Clarisse Lafont AU - Gilles Chattelier AU - Mathieu Marx Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/17/2020.07.08.20148692.abstract N2 - Objective Anosmia has been listed as a key-symptom associated with the COVID-19 infection. Because it often occurs without any sign of rhinitis, lesions of the central olfactory system have been suspected. To date, however, there is no evidence that anosmia caused by SARS-CoV2 could be the result of brain damage.Methods We conducted a case-series on 10 consecutive COVID-19 patients who reported anosmia. Each patient prospectively underwent a validated olfactory test (Sniffin’ Sticks test) and a brain MRI. Results Hypersignal intensity lesions of the central olfactory system were found in 3 subjects on 3D T2 FLAIR and 2D T2 High Resolution images with a lesion involving the olfactory bulbs and/or the orbitofrontal cortex. These 3 subjects showed a severe and persistent loss of smell on the olfactory test. Mucosal hyperplasia of the upper nasal cavities was found in two other subjects with significant smell disorders. There was no MRI anomaly in two subjects with good smell restoration.Conclusions Anomalies of the central olfactory system could be responsible for anosmia in patients with COVID-19 infection. Further studies are needed to assess the impact on long-term functional prognosis of these lesions.Key Result Central anomalies of the olfactory bulb and cortex could be responsible for anosmia in COVID-19 infectionCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Assistance Publique des Hopitaux de Paris - APHPAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB registration : #00011928 CERAPHP.5 Comite d'ethique de la recherche AP-HP.5 15 Rue de l'Ecole de Medecine, 75006 Paris Courriel : contact.ceraphp5@listes.parisdescartes.frAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData generated and analyzed are available upon request from the corresponding author: Yannick Girardeau Hopital Europeen Georges Pompidou - DIH - 20 Rue Leblanc, 75015 Paris e-mail: yannick.girardeau@aphp.fr COVID-19Coronavirus Disease 2019OBOlfactory BulbSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2 ER -